Anika Therapeutics (ANIK) Profit After Tax (2010 - 2026)

Anika Therapeutics (ANIK) has reported Profit After Tax for 17 consecutive years, with $3.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Profit After Tax rose 171.21% year-over-year to $3.3 million in Q2 2026; TTM through Jun 2026 was -$4.0 million, a 93.53% increase from a year earlier, with the FY2025 full-year figure at -$10.9 million, up 80.99% from the prior year.
• Profit After Tax was $3.3 million for Q2 2026 at Anika Therapeutics, up from -$5.1 million in the prior quarter.
• Over five years, Profit After Tax peaked at $3.3 million in Q2 2026 and troughed at -$62.9 million in Q4 2023.
• A 5-year average of -$9.4 million and a median of -$4.6 million in 2024 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax tumbled 5180.68% in 2025 and surged 171.21% in 2026, its largest moves.
• Over 5 years, Profit After Tax stood at -$3.9 million in 2022, then plunged by 1531.53% to -$62.9 million in 2023, then soared by 63.89% to -$22.7 million in 2024, then soared by 103.96% to $900000.0 in 2025, then surged by 267.67% to $3.3 million in 2026.
• The last three Profit After Tax figures came in at $3.3 million (Q2 2026), -$5.1 million (Q1 2026), and $900000.0 (Q4 2025), per Business Quant data.